Page last updated: 2024-08-21

pyrazines and riluzole

pyrazines has been researched along with riluzole in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barbera, S; Bigini, P; De Paola, M; Fumagalli, E; Mennini, T	1
Cedarbaum, JM; Chen, M; Cudkowicz, ME; Hansen, RL; Jones, D; Lee, J; Mahoney, K; Malik, F; Mao, J; Maragakis, N; Russell, AJ; Saikali, K; Shefner, J; Watson, ML; Wolff, AA	1
Scott, A	1

Trials

1 trial(s) available for pyrazines and riluzole

Article	Year
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 2012, Volume: 13, Issue:5 Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Female; Hand Strength; Humans; Imidazoles; Male; Middle Aged; Muscle, Skeletal; Neuroprotective Agents; Pyrazines; Riluzole; Treatment Outcome	2012

Article

Year

Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 2012, Volume: 13, Issue:5

Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Female; Hand Strength; Humans; Imidazoles; Male; Middle Aged; Muscle, Skeletal; Neuroprotective Agents; Pyrazines; Riluzole; Treatment Outcome

2012

Other Studies

2 other study(ies) available for pyrazines and riluzole

Article	Year
Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. Experimental neurology, 2006, Volume: 198, Issue:1 Topics: Animals; Body Weight; Brain-Derived Neurotrophic Factor; CD11b Antigen; Cell Death; Choline O-Acetyltransferase; Disease Models, Animal; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Imidazoles; Immunohistochemistry; Mice; Mice, Neurologic Mutants; Motor Activity; Motor Neurons; Neurodegenerative Diseases; Psychomotor Performance; Pyrazines; Radioimmunoassay; Riluzole	2006
Drug therapy: On the treatment trail for ALS. Nature, 2017, 10-18, Volume: 550, Issue:7676 Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Edaravone; Genetic Therapy; Humans; Imidazoles; Mesenchymal Stem Cells; Motor Neurons; Neuroglia; Off-Label Use; Oligoribonucleotides, Antisense; Piperidines; Precision Medicine; Pyrazines; Pyridines; Riluzole; RNAi Therapeutics; Stem Cell Transplantation; Superoxide Dismutase; Thiazoles; United States; United States Food and Drug Administration	2017

Article

Year

Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease.

Experimental neurology, 2006, Volume: 198, Issue:1

Topics: Animals; Body Weight; Brain-Derived Neurotrophic Factor; CD11b Antigen; Cell Death; Choline O-Acetyltransferase; Disease Models, Animal; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Imidazoles; Immunohistochemistry; Mice; Mice, Neurologic Mutants; Motor Activity; Motor Neurons; Neurodegenerative Diseases; Psychomotor Performance; Pyrazines; Radioimmunoassay; Riluzole

2006

Drug therapy: On the treatment trail for ALS.

Nature, 2017, 10-18, Volume: 550, Issue:7676

Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Edaravone; Genetic Therapy; Humans; Imidazoles; Mesenchymal Stem Cells; Motor Neurons; Neuroglia; Off-Label Use; Oligoribonucleotides, Antisense; Piperidines; Precision Medicine; Pyrazines; Pyridines; Riluzole; RNAi Therapeutics; Stem Cell Transplantation; Superoxide Dismutase; Thiazoles; United States; United States Food and Drug Administration

2017